The Virtual Lab: Al Agents Design New SARS-CoV-2 Nanobodies with Experimental Validation
Researchers used an AI-driven “Virtual Lab” to design nanobodies against the SARS-CoV-2 spike protein. Out of 92 computationally designed nanobodies, two showed promising binding profiles to newer variants in initial ELISA binding assays, suggesting potential for further development. Further validation is needed to confirm the efficacy of these nanobodies in a biological context and assess the Virtual Lab's broader applicability.